
|Articles|March 15, 2002
InSite obtains rights to optineurin gene
A test for the optineurin gene will be available to ophthalmologists soon - possibly this year and certainly by 2003, said S. Kumar Chandrasekaran, PhD, CEO of InSite Vision, Alameda, CA.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Sight Sciences reports new data supporting long-term efficacy of OMNI Surgical System
2
When policy meets parenthood: Examining residency leave in ophthalmology
3
Post-hoc AREDS2 analysis highlights distinct mechanisms driving GA progression
4
AAO 2025: Effect of cryopreserved amniotic membrane after corneal cross-linking in patients with keratoconus
5



















































.png)


